Smith D J, Evans H J, Newman J, Chapple C R
Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Br J Urol. 1994 Apr;73(4):409-12. doi: 10.1111/j.1464-410x.1994.tb07605.x.
To assess the potential value of ectopic beta-human chorionic gonadotrophin (beta HCG) measurement in the clinical management of transitional cell carcinoma (TCC).
A prospective serological study of 163 consecutive patients undergoing cystoscopy as new or review cases was performed to assess any correlation between beta HCG production and histological grading or stage.
Ten per cent of patients with TCC had a raised beta HCG level but there was no correlation with tumour differentiation, staging or prognosis.
beta HCG has no role as a tumour marker for TCC and therefore appears unlikely to play a part in the clinical management or treatment of urothelial tumours.
评估异位β-人绒毛膜促性腺激素(β-HCG)检测在移行细胞癌(TCC)临床管理中的潜在价值。
对163例因初次就诊或复诊而接受膀胱镜检查的患者进行了一项前瞻性血清学研究,以评估β-HCG产生与组织学分级或分期之间的相关性。
10%的TCC患者β-HCG水平升高,但与肿瘤分化、分期或预后无关。
β-HCG不作为TCC的肿瘤标志物,因此似乎不太可能在尿路上皮肿瘤的临床管理或治疗中发挥作用。